Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1935 - Expression of calreticulin is a novel independent prognostic factor for oral squamous cell carcinoma


09 Oct 2016


Poster display


Takanori Takenawa


Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376


T. Takenawa, K. Harada, T. Ferdous, Y. Ueyama

Author affiliations

  • Oral And Maxillofacial Surgery, Yamaguchi University Graduate School of Medicine, 755-8505 - Ube/JP


Abstract 1935


We focused on Calreticulin (CALR) on the basis of proteomic differential display analysis data using the regressive murine fibrosarcoma cell clone QR-32 and the progressive malignant tumor cell clone QRsP-11, derived from QR-32. CALR is an endoplasmic reticulum luminal Ca2 + -binding chaperone protein. CALR is thought to affect the tumor behavior of various malignancies. The purpose of this study was to determine whether CALR expression could be a useful prognostic factor in patients with oral squamous cell carcinoma (OSCC).


CALR expression was investigated by immunohistochemistry in tissue samples from 111 patients with OSCC. The association between CALR expression and clinicopathological characteristics, and patient survival were analyzed.


Immunohistchemical staining of CALR was observed in the cytoplasm of the cancer cells. Among 111 OSCC patients, high expression of CALR was observed in 44 patients (39.6%), whereas 67 patients (60.4%) showed low expression of CALR. Significant association was found between CALR expression and T classification (p = 0.0027), N classification (p = 0.0219), stage (p = 0.0013), and patient outcome (p = 0.0014). The 3-year survival rates of patients with CALR high- and low-expression tumors were 50.1% and 86.6% respectively, which was significantly different (p 


These results suggest that elevated expression of CALR might play an important role in the progression of OSCC and could be considered as a useful prognostic factor in patients with OSCC.

Clinical trial identification

Legal entity responsible for the study

Yamaguchi University Graduate School of Medicine


Grant-in-Aid from the Japanese Ministry of Education, Science and Culture


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings